D. Tam

发表

Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons.

G. Drewes, M. Bantscheff, N. Ramsden, 2011, ACS chemical biology.

Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.

R. Motter, M. Adler, H. Sham, 2013, Bioorganic & medicinal chemistry letters.

Triazolopyridazine LRRK2 kinase inhibitors.

M. Adler, H. Sham, M. Franzini, 2013, Bioorganic & medicinal chemistry letters.

Characterization of a KDM5 Small Molecule Inhibitor with Antiviral Activity against Hepatitis B Virus

Gregg A. Czerwieniec, Helen Yu, T. Appleby, 2022, bioRxiv.

Novel cinnoline-based inhibitors of LRRK2 kinase activity.

R. Neitz, M. Adler, H. Sham, 2013, Bioorganic & medicinal chemistry letters.

Woolly Monkey–HBV Infection in Squirrel Monkeys as a Surrogate Nonhuman Primate Model of HBV Infection

R. Lanford, E. Salas, W. Delaney, 2020, Hepatology communications.

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases Experimental Therapeutics, Molecular Targets, and Chemical Biology

K. Yamaguchi, J. Greshock, R. Wooster, 2009 .

A Selective and Oral Small Molecule Inhibitor of VEGFR-2 and VEGFR-1 Inhibits Neovascularization and Vascular Permeability

G. Mcmahon, Neela Patel, K. Leahy, 2003 .

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

J. Funk, Patrick F. Smith, S. Gourlay, 2017, British journal of clinical pharmacology.

Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus

Gregg A. Czerwieniec, Helen Yu, T. Appleby, 2022, bioRxiv.

The oxidative mechanism of action of ortho-quinone inhibitors of protein-tyrosine phosphatase alpha is mediated by hydrogen peroxide.

Stefan Vasile, Terence Hui, Gerald McMahon, 2004, Archives of biochemistry and biophysics.

Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).

J. M. Bradshaw, E. Verner, D. Goldstein, 2022, Journal of medicinal chemistry.

Prolonged and tunable residence time using reversible covalent kinase inhibitors

J. M. Bradshaw, Jack Taunton, Sergei Romanov, 2015, Nature chemical biology.

Discovery of a new class of glucosylceramide synthase inhibitors.

J. Nuss, S. Richards, P. Lamb, 2011, Bioorganic & medicinal chemistry letters.

Discovery and characterization of an inhibitor of glucosylceramide synthase.

K. Ogilvie, J. Nuss, S. Richards, 2012, Journal of medicinal chemistry.

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

K. Yamaguchi, J. Greshock, R. Wooster, 2009, Cancer research.

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.

J. M. Bradshaw, M. Gerritsen, E. Venetsanakos, 2017, Journal of medicinal chemistry.

Selective and Brain‐Permeable Polo‐like Kinase‐2 (Plk‐2) Inhibitors That Reduce α‐Synuclein Phosphorylation in Rat Brain

Kent Fitzgerald, Paul Beroza, Lee Latimer, 2013, ChemMedChem.

Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.

P. Beroza, R. Motter, R. Neitz, 2013, Bioorganic & medicinal chemistry letters.

Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates.

Paul Beroza, Zhao Ren, Dean R Artis, 2013, Bioorganic & medicinal chemistry letters.

Design and synthesis of thiophene dihydroisoquinolines as novel BACE1 inhibitors.

P. Beroza, Jiangli Yan, H. Sham, 2013, Bioorganic & medicinal chemistry letters.

A Selective and Oral Small Molecule Inhibitor of Vascular Epithelial Growth Factor Receptor (VEGFR)-2 and VEGFR-1 Inhibits Neovascularization and Vascular Permeability

A. Howlett, G. Mcmahon, Qingling Zhang, 2003, Journal of Pharmacology and Experimental Therapeutics.

The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance

J. M. Bradshaw, M. Gerritsen, E. Venetsanakos, 2017, Molecular Cancer Therapeutics.

Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells.

G. Mcmahon, M. Bova, D. Tam, 2005, Toxicology letters.

In vivo pharmacodynamics of GS-5801, a liver targeted prodrug of a lysine demethylase 5 inhibitor with antiviral activity against hepatitis B virus

W. Delaney, B. Feierbach, C. Snyder, 2017 .

Development of a Novel β-Secretase Binding Assay Using the AlphaScreen Platform

H. Cheung, H. Sham, M. Bova, 2013, Journal of biomolecular screening.

Novel cinnoline-based inhibitors of LRRK2 kinase activity.

M. Adler, H. Sham, M. Franzini, 2013, Bioorganic & medicinal chemistry letters.

Antiviral activity of GS-5801, a liver-targeted prodrug of a lysine demethylase 5 inhibitor, in a hepatitis B virus primary human hepatocyte infection model

T. Appleby, W. Delaney, B. Feierbach, 2017 .

Selective and Brain‐Permeable Polo‐like Kinase‐2 (Plk‐2) Inhibitors That Reduce α‐Synuclein Phosphorylation in Rat Brain

P. Beroza, R. Motter, R. Neitz, 2013, ChemMedChem.